1. Academic Validation
  2. Chemical and Antiplasmodial Investigations on Eremophila-Derived Alkaloids and Semisynthetic Ether Analogues

Chemical and Antiplasmodial Investigations on Eremophila-Derived Alkaloids and Semisynthetic Ether Analogues

  • J Nat Prod. 2024 Apr 26;87(4):849-854. doi: 10.1021/acs.jnatprod.3c01072.
Chen Zhang 1 Kah Yean Lum 1 Jonathan M White 2 Sandra Duffy 3 Aaron M Lock 3 Vicky M Avery 3 Rohan A Davis 1 4
Affiliations

Affiliations

  • 1 Griffith Institute for Drug Discovery, School of Environment and Science, Griffith University, Brisbane, QLD 4111, Australia.
  • 2 School of Chemistry and Bio21 Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.
  • 3 Discovery Biology, Centre for Cellular Phenomics, School of Environment and Science, Griffith University, Brisbane, QLD 4111, Australia.
  • 4 NatureBank, Griffith Institute for Drug Discovery, Griffith University, Brisbane, QLD 4111, Australia.
Abstract

Microthecaline A (1), the known antiplasmodial quinoline serrulatane alkaloid from the roots of Eremophila microtheca F. Muell. ex Benth. (Scrophulariaceae), was targeted for isolation and subsequent use in the generation of a semisynthetic ether library. A large-scale extraction and isolation yielded the previously undescribed quinoline serrulatane microthecaline B (2), along with crystalline 1 that enabled the first X-ray crystallographic analysis to be undertaken on this rare alkaloid structure class. The X-ray diffraction analysis of 1 supported the absolute configuration assignment of microthecaline A, which was originally assigned by ECD data analysis. Microthecaline A (1) was converted into 10 new semisynthetic ether derivatives (3-12) using a diverse series of commercially available alkyl halides. Chemical structures of the new serrulatane alkaloid and semisynthetic ether analogues were assigned by spectroscopic and spectrometric analyses. Antiplasmodial evaluations of 1-12 showed that the semisynthetic derivative 5 elicited the most potent activity with an IC50 value of 7.2 μM against Plasmodium falciparum 3D7 (drug-sensitive) strain.

Figures